# Melanoma Metastasized to the Brain and Steroids

> **NCT03563729** · PHASE2 · RECRUITING · sponsor: **Inge Marie Svane** · enrollment: 80 (estimated)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Pembrolizumab Injection [Keytruda]
- **DRUG:** Ipilimumab Injection [Yervoy]
- **DRUG:** Nivolumab Injection [Opdivo]
- **DRUG:** Encorafenib
- **DRUG:** Binimetinib
- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03563729
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-06-06
- **Primary completion:** 2024-06-01
- **Final completion:** 2028-06-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563729, "Melanoma Metastasized to the Brain and Steroids". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03563729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*